Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
10X Genomics is a health information services business based in the US. 10X Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10X Genomics employs 1,243 staff and has a trailing 12-month revenue of around $516.4 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $48.13 |
|---|---|
| 52-week range | $23.81 - $83.34 |
| 50-day moving average | $45.87 |
| 200-day moving average | $39.06 |
| Wall St. target price | $51.70 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.51 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $48.13 from 2023-03-17
| 1 week (2023-03-14) | -1.11% |
|---|---|
| 1 month (2023-02-21) | 0.06% |
| 3 months (2022-12-21) | 30.29% |
| 6 months (2022-09-21) | 59.21% |
| 1 year (2022-03-17) | -28.22% |
|---|---|
| 2 years (2021-03-19) | -72.92% |
| 3 years (2020-03-20) | 55.78 |
| 5 years (2018-03-17) | N/A |
| Revenue TTM | $516.4 million |
|---|---|
| Gross profit TTM | $396 million |
| Return on assets TTM | -10.25% |
| Return on equity TTM | -20.45% |
| Profit margin | -32.15% |
| Book value | $7.00 |
| Market capitalisation | $5.6 billion |
TTM: trailing 12 months
We're not expecting 10X Genomics to pay a dividend over the next 12 months.
10X Genomics's shares were split on a 1:2 basis on 16 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10X Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10X Genomics shares which in turn could have impacted 10X Genomics's share price.
Over the last 12 months, 10X Genomics's shares have ranged in value from as little as $23.81 up to $83.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 10X Genomics's is 1.731. This would suggest that 10X Genomics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.